Silexion Therapeutics exercises warrants, raising $3.3 million, plans for general corporate purposes.

From GlobeNewswire: 2025-01-29 17:30:00

Silexion Therapeutics Corp. (NASDAQ: SLXN) announced the immediate exercise of outstanding warrants to purchase up to 2,221,523 ordinary shares at $1.35 per share, totaling approximately $3.3 million in gross proceeds. The company will issue new unregistered warrants for an additional $0.125 per share, with an exercise price of $1.50 per share. The new warrants will be immediately exercisable and have a term of twenty-four months. These securities have not been registered under the 1933 Act and are intended for a private placement. The Company plans to use the net proceeds for general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.

Silexion Therapeutics is a biotech company developing RNA interference therapies for KRAS-driven cancers. Their product, LODER™, has shown promise in a Phase 2 trial for non-resectable pancreatic cancer. The company is also advancing SIL-204, a next-generation siRNA candidate targeting a broader range of KRAS mutations. The focus is on improving outcomes for patients with difficult-to-treat cancers. Forward-looking statements in this press release caution against undue reliance on projections due to potential risks and uncertainties. For more information, visit the company’s website.



Read more at GlobeNewswire: Silexion Therapeutics Announces Exercise of Warrants for